Abstract
Advances in the characterization of pain signaling in recent years indicate that distinct neurophysiological and neurochemical mechanisms contribute to pain arising from injury to the nervous system (neuropathic pain). Tissue injury results in the release of pro-nociceptive mediators that sensitize peripheral nerve terminals (peripheral sensitization), leading to neurochemical and phenotypic alterations of sensory neurons and increased excitability of spinal cord dorsal horn neurons (central sensitization). In addition, the response of the nervous system to pain is not static, but is modulated by descending systems originating in the brain that can modulate pain thresholds. In this review, attention is given to the experimental modeling of neuropathic pain in preclinical studies. Recently, an increased understanding of the neurophysiological plasticity of the nervous system in response to chronic pain has led to the discovery and development of novel pharmacological interventions that may have clinical utility in treating neuropathic pain.
Keywords: Neuropathic pain, spinal nerve ligation, chronic constriction injury, diabetic neuropathy, chemotherapy-induced neuropathy
Current Pharmaceutical Design
Title: Neuropathic Pain: Models and Mechanisms
Volume: 15 Issue: 15
Author(s): Janel M. Boyce-Rustay and Michael F. Jarvis
Affiliation:
Keywords: Neuropathic pain, spinal nerve ligation, chronic constriction injury, diabetic neuropathy, chemotherapy-induced neuropathy
Abstract: Advances in the characterization of pain signaling in recent years indicate that distinct neurophysiological and neurochemical mechanisms contribute to pain arising from injury to the nervous system (neuropathic pain). Tissue injury results in the release of pro-nociceptive mediators that sensitize peripheral nerve terminals (peripheral sensitization), leading to neurochemical and phenotypic alterations of sensory neurons and increased excitability of spinal cord dorsal horn neurons (central sensitization). In addition, the response of the nervous system to pain is not static, but is modulated by descending systems originating in the brain that can modulate pain thresholds. In this review, attention is given to the experimental modeling of neuropathic pain in preclinical studies. Recently, an increased understanding of the neurophysiological plasticity of the nervous system in response to chronic pain has led to the discovery and development of novel pharmacological interventions that may have clinical utility in treating neuropathic pain.
Export Options
About this article
Cite this article as:
Boyce-Rustay M. Janel and Jarvis F. Michael, Neuropathic Pain: Models and Mechanisms, Current Pharmaceutical Design 2009; 15 (15) . https://dx.doi.org/10.2174/138161209788186272
DOI https://dx.doi.org/10.2174/138161209788186272 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Modification in Neuropathic Pain
Current Pharmaceutical Design Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Regenerative Medicine in Retina: The Future Cure
Current Tissue Engineering (Discontinued) Properties and Potency of Small Molecule Agents for Treatment of Mycobacterium Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Synaptic Plasticity, Metaplasticity and Depression
Current Neuropharmacology Commentary [ Research Highlights(To miR or Not to miR: That is the Question in ALS Disease ]
CNS & Neurological Disorders - Drug Targets Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews Pharmaceutical Polymeric Nanoparticles Prepared by the Double Emulsion- Solvent Evaporation Technique
Recent Patents on Drug Delivery & Formulation Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Subject Index to Volume 2
Current Neuropharmacology Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Imaging of Wallerian Degeneration in the Brain
Current Medical Imaging Targeting the Prokineticin System to Control Chronic Pain and Inflammation
Current Medicinal Chemistry